Patrick I. Borgen, MD, Discusses Upcoming Breast Cancer Conferences

Video

The breast cancer expert discussed the importance of attending breast cancer meetings like the San Antonio Breast Cancer Symposium and the Miami Breast Cancer Conference.

Patrick I. Borgen, MD, chair of surgery and director of the Breast Cancer Program at Maimonides Medical Center, discussed the importance of attending breast cancer meetings like the San Antonio Breast Cancer Symposium and the Miami Breast Cancer Conference.

Transcription:

In December of this year, we will once again enjoy the San Antonio Breast Cancer Symposium. This is a very long running scientific meeting where a number of the seminal research discoveries over the years have been presented. And while we’re not supposed to really know what is coming out, I think that there are some very important clinical trials that are going to be unblinded and talked about. There are going to be some emerging agents that will play a bigger role. So, we are all very excited about San Antonio this year.

 

I will mention that while San Antonio shares where things are, it doesn’t really address how to apply them practically and I think that is where the Miami Breast Cancer Conference comes in to take the scientific knowledge from San Antonio and apply it practically. How do I take all of this information and apply it to the patient in front of me. And I think that is what Miami does.  

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content